Adam R. Craig - Jan 24, 2023 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
President and CEO, Director
Signature
Adam R. Craig
Stock symbol
CTIC
Transactions as of
Jan 24, 2023
Transactions value $
-$440,163
Form type
4
Date filed
1/26/2023, 04:17 PM
Previous filing
Jan 3, 2023
Next filing
Mar 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $70K +83.2K +282.61% $0.84* 113K Jan 24, 2023 Direct
transaction CTIC common stock Sale -$499K -83.2K -73.86% $6.00 29.4K Jan 24, 2023 Direct F1
transaction CTIC common stock Options Exercise $1.78K +2.12K +7.19% $0.84* 31.6K Jan 24, 2023 Direct
transaction CTIC common stock Sale -$12.7K -2.12K -6.71% $6.01 29.4K Jan 24, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -83.2K -14.98% $0.00 472K Jan 24, 2023 Common Stock 83.2K $0.84 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.12K -0.45% $0.00 470K Jan 24, 2023 Common Stock 2.12K $0.84 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.